Lipocine announced that two abstracts related to LPCN 2101 have been accepted for poster presentation at the 2025 American Epilepsy Society (AES) annual meeting.
LPCN 2101 is in development for the potential treatment of epilepsy.
The abstracts are embargoed from the AES online abstract database until Monday, November 24, 2025.
LPCN 2101 Abstracts Accepted
Two abstracts related to LPCN 2101 have been accepted for poster presentation at the 2025 AES annual meeting.
Focus on Epilepsy Treatment
LPCN 2101 is being developed for the potential treatment of epilepsy, addressing significant unmet medical needs.
Partnership Opportunities
Lipocine is exploring partnerships for various drug candidates, including LPCN 1107, LPCN 1154, LPCN 2401, LPCN 1148, and LPCN 1144.
- The acceptance of LPCN 2101 abstracts for presentation enhances Lipocine's visibility in the field of epilepsy treatment and showcases its innovative product development approach.
- Exploring partnerships for drug candidates indicates Lipocine's strategic focus on expanding its treatment options and addressing diverse medical needs.
Lipocine's involvement in the AES 2025 meeting highlights its commitment to advancing treatment options for epilepsy and other medical conditions through innovative drug development and potential partnerships.